Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2.

Proceedings of the National Academy of Sciences of the United States of America - 16 Mar 2021

Liu Rengyun, Tan Jie, Shen Xiaopei, Jiang Ke, Wang Chaoqun, Zhu Guangwu, Xing Mingzhao

Abstract excerpt

The telomerase reverse transcriptase (TERT) has long been pursued as a direct therapeutic target in human cancer, which is currently hindered by the lack of effective specific inhibitors of TERT. The FOS/GABPB/(mutant) TERT cascade plays a critical role in the regulation of mutant TERT, in which FOS acts as a transcriptional factor for GABPB to up-regulate the expression of GABPB, which in turn activates mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Isoxazoles

Share to Proto-Oncogene Proteins c-fos

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Share to Survivin

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 33836600
DOI: 10.1073/pnas.2022779118
PMCID: PMC7980366

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2.PMID 33836600Read ↗

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.Semantic proximity Read ↗

TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel.Semantic proximity Read ↗

P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathwaySemantic proximity Read ↗

SNAI2 cooperates with MEK1/2 and HDACs to suppress BIM- and BMF-dependent apoptosis in <i>TERT</i> promoter mutant cancersSemantic proximity Read ↗

TERT suppresses apoptotis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14-3-3 protein-binding ability.Semantic proximity Read ↗

Human telomerase catalytic subunit (hTERT) suppresses p53-mediated anti-apoptotic response via induction of basic fibroblast growth factorSemantic proximity Read ↗

Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NF-kappaB.Semantic proximity Read ↗

High-risk neuroblastoma: ATRX and TERT as prognostic markers and therapeutic targets. Review and update on the topic.Semantic proximity Read ↗

Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17Semantic proximity Read ↗

Discovery and characterization of a novel telomerase alternative splicing isoform that protects lung cancer cells from chemotherapy induced cell death.Semantic proximity Read ↗

TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways.Semantic proximity Read ↗

CHOP and caspase 3 induction underlie glioblastoma cell death in response to endoplasmic reticulum stressSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.